A Business Standard article titled Sanjiv Kaul continues multi-bagger pharma returns with Eris’ IPO, quotes Venture Intelligence data on ChrysCapital’s exits in the pharmaceuticals space:
In 2015, Chrys Capital exited Mankind Pharma in a secondary deal worth $203 million to Capital International, getting 13 times return made on $24 million investment done in 2007.
A year prior to that it made over 17 times return by partially selling its investment in Ahmedabad-based Intas Pharmaceuticals for $131 million to Temasek Holdings. It made another exit from Intas this year at a return multiple of 4.6 times in a $106 million secondary deal to a bunch of buyers including Capital International. It had invested in Intas first in 2005 for $12 million and then had followed up with $57 million in 2012.
Venture Intelligence is India’s longest serving provider of data and analysis on Private Company Financials, Transactions (private equity, venture capital and M&A) & their Valuations in India.
